Lv3
240 积分 2024-11-27 加入
Surrogate endpoints for overall survival (OS) in advanced pancreatic cancer (APC): Analysis of randomized clinical trials (RCTs) exploring gemcitabine (G)-based combinations
10天前
已关闭
Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials
10天前
已完结
The 30% reduction of baseline CA19-9 could stratify the prognosis of advanced pancreatic ductal adenocarcinoma with RECIST stable disease after first-line chemotherapy
15天前
已完结
Changes in CTCAE v6: Effect on dose-escalation and dose-limiting toxicity with repeat analysis of recent clinical trials
22天前
已完结
Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer
4个月前
已关闭
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
11个月前
已完结
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
1年前
已完结
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
1年前
已完结
Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia
1年前
已完结
皖公网安备34019202002308
